Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
130M
-
Number of holders
-
342
-
Total shares
-
107M
-
Shares change
-
-679K
-
Total reported value, excl. options
-
$13.9B
-
Value change
-
-$101M
-
Put/Call ratio
-
1.2
-
Number of buys
-
154
-
Number of sells
-
-151
-
Price
-
$129.97
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY) as of Q4 2020
372 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - Common Stock as of Q4 2020.
ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY) has 342 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 107M shares
of 130M outstanding shares and own 82.01% of the company stock.
Largest 10 shareholders include FMR LLC (16.1M shares), VANGUARD GROUP INC (10.5M shares), WELLINGTON MANAGEMENT GROUP LLP (10.1M shares), BAILLIE GIFFORD & CO (9.13M shares), BlackRock Inc. (8.72M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.58M shares), Dodge & Cox (4.64M shares), STATE STREET CORP (2.8M shares), JPMORGAN CHASE & CO (2.3M shares), and MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (1.76M shares).
This table shows the top 342 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.